Skip survey header

sHTG Disorders in Clinical Practice: Using Familial Chylomicronemia Syndrome to Highlight Diagnosis and Management

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine (PIM) and the Cardiovascular Institute of Philadelphia. In support of improving patient care, Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA: PIM designates this live activity for a maximum of 2.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA: PIM designates this activity for 2.50 AAPA Category 1 CME credits. Physician Associates should claim only the credit commensurate with the extent of their participation in the activity.

ANCC: PIM designates this activity for 2.50 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

ACPE: PIM designates this continuing education activity for 2.50 contact hour(s) (.25) of the Accreditation Council for Pharmacy Education. Universal Activity Number – JA4008162-9999-26-082-L01-P

1. How frequently do you encounter patients with triglyceride levels ≥500 mg/dL? *This question is required.
2. *This question is required.
3. Which of the following statements is true?
4. Which of the following patients is most likely to have FCS?: *This question is required.
5. A 28 year old male presents for a follow-up in clinic following a recent admission for his 5th acute pancreatitis event with TG > 7000 on presentation. His BMI is 24. He is a non-smoker and reports no recent alcohol use. He does not have diabetes, hypertension, and reports he is otherwise healthy. He is not on any medications. What therapy should be considered in his treatment plan? *This question is required.
6. Olezarsen and plozasiran are apoC-III lowering therapies that are FDA-approved for which indication: *This question is required.
7. Click below to view the program on-demand
0%